Galmed Pharmaceuticals(GLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLMD Galmed Pharmaceuticals

Post-Mkt 05-21 16:31:44 EDT

0.5801

-0.0239

-3.96%

盘后0.5838

+0.0037+0.64%

16:00 EDT

High0.6085	Low0.5800	Vol42.24K
Open0.6085	D1 Closing0.6040	Amplitude4.72%
Mkt Cap3.82M	Tradable Cap3.77M	Total Shares6.58M
T/O24.84K	T/O Rate0.65%	Tradable Shares6.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GLMD","market":"US","secType":"STK","nameCN":"Galmed Pharmaceuticals","latestPrice":0.5801,"timestamp":1779393600000,"preClose":0.604,"halted":0,"volume":42241,"hourTrading":{"tag":"盘后","latestPrice":0.5838,"preClose":0.5801,"latestTime":"16:00 EDT","volume":67,"amount":39.114599999999996,"timestamp":1779393601301,"change":0.0037,"changeRate":0.006378,"amplitude":0},"delay":0,"changeRate":-0.03956953642384112,"floatShares":6505700,"shares":6581400,"eps":-2.391145,"marketStatus":"Post-Mkt","change":-0.0239,"latestTime":"05-21 16:31:44 EDT","open":0.6085,"high":0.6085,"low":0.58,"amount":24837,"amplitude":0.047185,"askPrice":0.6556,"askSize":2,"bidPrice":0.57,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.391145,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779408000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1394683200000,"exchange":"NASDAQ","adjPreClose":0.604,"preHourTrading":{"tag":"盘前","latestPrice":0.599,"preClose":0.6024,"latestTime":"08:49 EDT","volume":5,"amount":2.995,"timestamp":1779367766536,"change":-0.0034,"changeRate":-0.005644,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.5838,"preClose":0.5801,"latestTime":"16:00 EDT","volume":67,"amount":39.114599999999996,"timestamp":1779393601301,"change":0.0037,"changeRate":0.006378,"amplitude":0},"volumeRatio":0.158693,"impliedVol":0.7031,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/GLMD/wiki","defaultTab":"wiki","newsList":[{"id":"2636307559","title":"Galmed Pharmaceuticals Ltd  expected to post a loss of 38 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2636307559","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636307559?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:39","pubTimestamp":1779107946,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd  expected to post a loss of38cents a share - Earnings Preview Galmed Pharmaceuticals Ltd GLMD.OQ GLMD.O is expected to  report results on May 20 (estimated) for the period e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nL8N41V14E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635712585","title":"Galmed reports results from first-in-man PK study of Aramchol Meglumine","url":"https://stock-news.laohu8.com/highlight/detail?id=2635712585","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635712585?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:53","pubTimestamp":1778759584,"startTime":"0","endTime":"0","summary":"Galmed (GLMD) announced milestone results from a Phase 1 PK study in healthy subjects. The overall objective of the study was to identify the dose ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/galmed-reports-results-from-first-in-man-pk-study-of-aramchol-meglumine-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/galmed-reports-results-from-first-in-man-pk-study-of-aramchol-meglumine-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PK","BK4139","GLMD","BK4218","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635711794","title":"Galmed Announces Results From First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (Am); 400Mg Am Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (Aa) 300Mg","url":"https://stock-news.laohu8.com/highlight/detail?id=2635711794","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635711794?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:30","pubTimestamp":1778758202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA62ZYRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633133595","title":"Galmed Pharmaceuticals Partners with Tissue Dynamics on Human Cardiac Fibrosis Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2633133595","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633133595?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:19","pubTimestamp":1778069945,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Galmed Pharmaceuticals ( ($GLMD) ). On May 6, 2026, Galmed Pharmaceuticals and Tissue Dynamics announced a coll...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-partners-with-tissue-dynamics-on-human-cardiac-fibrosis-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-partners-with-tissue-dynamics-on-human-cardiac-fibrosis-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633877101","title":"Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2633877101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633877101?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:31","pubTimestamp":1778067085,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nFWN41J0IB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633293187","title":"Galmed partners Tissue Dynamics to develop chronic cardiac fibrosis organoid platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2633293187","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633293187?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:30","pubTimestamp":1778067050,"startTime":"0","endTime":"0","summary":"Galmed entered collaboration with Tissue Dynamics to build human cardiac fibrosis platform aimed at advancing Aramchol-based therapeutics.Program targets chronic post-myocardial infarction remodeling, also HFpEF, using vascularized multichamber cardiac organoids with embedded metabolic sensors.DynamiX platform designed to run more than 20,000 organoids in parallel, generating longitudinal readouts to support candidate selection, dosing strategy, combinations, and stage-specific interventions.Effort centers on links between lipid metabolism, SCD1 activity, fibrosis, impaired tissue repair, positioning platform as preclinical engine for new cardiac fibrosis drug development.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL62Blf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627235186","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galmed Pharmaceuticals (GLMD), Neurocrine (NBIX) and Mesoblast (MESO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627235186","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627235186?lang=en_us&edition=fundamental","pubTime":"2026-04-15 23:00","pubTimestamp":1776265224,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Galmed Pharmaceuticals (GLMD), Neurocrine (NBIX) a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-galmed-pharmaceuticals-glmd-neurocrine-nbix-and-mesoblast-meso-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-galmed-pharmaceuticals-glmd-neurocrine-nbix-and-mesoblast-meso-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0128526141.USD","LU0154245673.USD","BK4139","LU0154245756.USD","LU0029874061.USD","NBIX","LU0109394709.USD","LU0889565916.HKD","LU2065170008.USD","LU2065171402.SGD","MESO","GLMD","LU0320765992.SGD","LU2324357040.USD","BK4581","LU2065169927.USD","LU0823416689.USD","XBI","BK4588","LU2065171311.SGD","HCSG","BK4137","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627441678","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere","url":"https://stock-news.laohu8.com/highlight/detail?id=2627441678","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627441678?lang=en_us&edition=fundamental","pubTime":"2026-04-14 21:15","pubTimestamp":1776172541,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, TravereWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nL6N40X0IU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRCE","TSLW","SPOG","TE","EAF","CDE","NWMX","WMG","HL","CWVX","BE","TSLL","TESL","TVTX","GSAT","FRDU","AVXL","UAL","LUV","JNJ","DAL","CMND","TSLG","GM","BEZ","TLA","AU","DOW","F","CAT","CMPS","CRDO","HOTH","ORCL","ORCU","SPOT","TSLA","TSLT","AVNS","AAL","LCID","CRWV","KMX","CRWG","NNOX","TSLQ","ACI","BLK","GLMD","NEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445597","title":"Galmed Pharmaceuticals Teams with Tel Aviv University on Aramchol for Metastatic Brain Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445597","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445597?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:57","pubTimestamp":1776167861,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Galmed Pharmaceuticals ( ($GLMD) ). On April 14, 2026, Galmed Pharmaceuticals announced a research collaboratio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-teams-with-tel-aviv-university-on-aramchol-for-metastatic-brain-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-teams-with-tel-aviv-university-on-aramchol-for-metastatic-brain-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627443351","title":"Galmed partners with Tel Aviv University to test Aramchol in brain metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2627443351","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627443351?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:31","pubTimestamp":1776166305,"startTime":"0","endTime":"0","summary":"Galmed signed research collaboration agreement with Ramot at Tel Aviv University to evaluate brain-penetrant SCD1 inhibitor Aramchol as targeted therapy for metastatic brain cancer.Program targets p53-deficient brain metastases based on TAU findings linking p53 inactivation to SCD1 upregulation that supports tumor growth in brain.Work will use TAU 3D in vitro systems plus in vivo brain-metastasis models to assess Aramchol efficacy.Collaboration aims to support Galmed oncology development strategy, including ongoing clinical work in colorectal cancer where p53 mutations are common.Galmed said overall 2-year survival for brain metastasis remains below 10%, underscoring need for new targeted therapies.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL89MDC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627480164","title":"Galmed Announces a Collaboration Agreement With Tel Aviv University to Evaluate Its Scd1 Inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2627480164","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627480164?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:30","pubTimestamp":1776166200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUABQXJVN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626231134","title":"BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman","url":"https://stock-news.laohu8.com/highlight/detail?id=2626231134","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626231134?lang=en_us&edition=fundamental","pubTime":"2026-04-10 01:51","pubTimestamp":1775757106,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-FormanWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a6220b127d3bbee7041552a4a4e77ac3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nL6N40S0MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRGV","TEM","ADSK","WSR","APLD","CRWV","NOW","STZ","ANVS","TSLP","FBRX","TSLA","GDRX","HRL","GLMD","BLSG","TSLI","MVLL","WW","IDYA","MRVL","AZYY","TEMT","TSLL","CAT","KYMR","TSL","CRWU","NOC","TSLO","TSLQ","SMPL","CRWG","TSLR","OXY","AMZN","RELL","CG","CRSH","FDX","BLSX","CORD","NUAI","TSLS","BLSH","MRVU","VNDA","CCCC","STAA","TSLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626824561","title":"Why Is Galmed Pharmaceuticals Stock (GLMD) Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626824561","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626824561?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:36","pubTimestamp":1775738206,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals stock took off today alongside an update on the company’s Parkinson disease treatment, Aramchol.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-galmed-pharmaceuticals-stock-glmd-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-galmed-pharmaceuticals-stock-glmd-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626845201","title":"BUZZ-Galmed jumps on lab data on new brain-penetrating version of experimental drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2626845201","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626845201?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:05","pubTimestamp":1775736348,"startTime":"0","endTime":"0","summary":"BUZZ-Galmed jumps on lab data on new brain-penetrating version of experimental drug** Shares of biotech firm Galmed Pharmaceuticals GLMD.O jump 68% to $1.05 premarket** Co says it developed a new formulation of its experimental drug Aramchol that can reach the brain, targeting Parkinson's and similar brain diseases that affect movement and thinking** Co says lab tests showed the new version lowered levels of a disease-linked protein and was not toxic in early studies** The new formulation uses tiny fat-based particles to help the drug cross the brain's natural protective barrier, co says** Co plans early-stage human trials in the second half of 2026, pending regulatory approval - GLMD** Parkinson's is a brain disorder where harmful proteins build up and slowly damage nerve cells; there are no treatments that slow the disease** As of last close, stock was down ~17% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nL4N40S0YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626218977","title":"Galmed Pharmaceuticals Ltd - Develops Brain-Penetrating Formulation of Aramchol With Barcode Nanotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2626218977","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626218977?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:34","pubTimestamp":1775734498,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0L0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626918971","title":"Galmed plans Phase 1b/2 Parkinson’s trial for brain-penetrating Aramchol in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626918971","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626918971?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:32","pubTimestamp":1775734353,"startTime":"0","endTime":"0","summary":"Galmed unveiled a brain-penetrating formulation of Aramchol that it aims to advance into a proof-of-concept Phase 1b/2 study in Parkinson disease patients in H2 2026.Results have not been presented; preliminary in-vitro findings were referenced, with Aramchol described as reducing alpha-synuclein aggregation without signs of toxicity.Program targets synucleinopathies where no disease-modifying therapies are available, positioning Aramchol as a potential first-in-class SCD1 inhibitor for central nervous system use.Delivery strategy uses lipid nanoparticles designed to cross blood-brain barrier, with subcutaneous administration planned.Development work was conducted with Barcode Nanotech, using in vivo screening and AI tools to select formulation intended to improve brain delivery.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL8BSnc2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624300530","title":"Galmed net loss widens 37% to $10 million in FY25","url":"https://stock-news.laohu8.com/highlight/detail?id=2624300530","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624300530?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:23","pubTimestamp":1774988611,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals widened net loss 37% to $10.3 million for the year ended Dec. 31, 2025.Research and development expense jumped 64% to $4.9 million, due to higher clinical trial costs.Cash and cash equivalents totaled $4.0 million, while current assets rose to $18.6 million.Galmed said existing funds should support operations for more than 12 months from the annual report’s issuance date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLbgTccv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622821993","title":"Galmed Pharmaceuticals Ltd  expected to post a loss of 51 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821993","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622821993?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:44","pubTimestamp":1774615449,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals Ltd  expected to post a loss of51cents a share - Earnings Preview Galmed Pharmaceuticals Ltd GLMD.OQ GLMD.O is expected to  report resultson March 31 (estimated) for the period ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F10T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620325863","title":"Galmed Pharmaceuticals Ltd. CFO Doron Leib Cohen files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620325863","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620325863?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:46","pubTimestamp":1773834392,"startTime":"0","endTime":"0","summary":"Galmed reported an initial statement of beneficial ownership by Doron Leib Cohen, its Chief Financial Officer. Cohen reported direct beneficial ownership of 22,083 ordinary shares. Cohen also reported direct beneficial ownership of 50,416 restricted share units. Cohen reported options to purchase 208 ordinary shares at an exercise price of USD 68.4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL8Wx2Cy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620258686","title":"Galmed Pharmaceuticals COO Nehemya Guy files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620258686","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620258686?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:46","pubTimestamp":1773834389,"startTime":"0","endTime":"0","summary":"Galmed reported an initial statement of beneficial ownership for Nehemya Guy, its chief operating officer. Guy reported direct ownership of 22,116 ordinary shares. He also reported direct ownership of 50,416 restricted share units. Guy reported options to purchase 666 ordinary shares at an exercise price of USD 68.4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL221wjB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.galmedpharma.com","stockEarnings":[{"period":"1week","weight":0.0146},{"period":"1month","weight":-0.1999},{"period":"3month","weight":0.0578},{"period":"6month","weight":-0.2785},{"period":"1year","weight":-0.5591},{"period":"ytd","weight":-0.1952}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.0459},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.2503},{"period":"ytd","weight":0.087}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.024694},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.055438},{"month":3,"riseRate":0.25,"avgChangeRate":-0.083341},{"month":4,"riseRate":0.538462,"avgChangeRate":-0.000255},{"month":5,"riseRate":0.461538,"avgChangeRate":-0.078317},{"month":6,"riseRate":0.75,"avgChangeRate":0.160804},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.094546},{"month":8,"riseRate":0.25,"avgChangeRate":-0.058125},{"month":9,"riseRate":0.5,"avgChangeRate":0.034812},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.138105},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.048693},{"month":12,"riseRate":0.416667,"avgChangeRate":0.037621}],"exchange":"NASDAQ","name":"Galmed Pharmaceuticals","nameEN":"Galmed Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Galmed Pharmaceuticals(GLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Galmed Pharmaceuticals(GLMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Galmed Pharmaceuticals,GLMD,Galmed Pharmaceuticals股票,Galmed Pharmaceuticals股票老虎,Galmed Pharmaceuticals股票老虎国际,Galmed Pharmaceuticals行情,Galmed Pharmaceuticals股票行情,Galmed Pharmaceuticals股价,Galmed Pharmaceuticals股市,Galmed Pharmaceuticals股票价格,Galmed Pharmaceuticals股票交易,Galmed Pharmaceuticals股票购买,Galmed Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Galmed Pharmaceuticals(GLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Galmed Pharmaceuticals(GLMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}